Use of gene therapy in central nervous system repair.
Recent advances have increased our molecular understanding of the central nervous system (CNS), in both health and disease. In order to realize the clinical benefits of these findings, new molecular-based therapies need to be developed, such as CNS gene therapy. Although the field has suffered setbacks, it remains an attractive technology for providing new therapies in the post-genomic world. The development of new vectors, and their extensive application in animal models of CNS disease, provides evidence suggesting that gene therapy will eventually become an accepted clinical option. In fact, the first gene therapy clinical trial for Parkinson's disease has recently begun. This review discusses how gene therapy has been applied in animal models, and how it may be used to repair the damage caused by CNS diseases and trauma in human beings. Furthermore, it explores how such treatments may be combined with, and augment, more conventional therapeutic approaches.
Tinsley
R
R
Department of Clinical Neuroscience, Sahlgrenska University Hospital, Göteborg, Sweden. rogan.tinsley@neuro.gu.se
Eriksson
P
P
D000818:Animals; D002493:Central Nervous System Diseases / Q000235:genetics* / Q000628:therapy*; D004195:Disease Models, Animal; D015316:Genetic Therapy; D005822:Genetic Vectors; D006801:Humans; D010300:Parkinson Disease / Q000235:genetics / Q000628:therapy